“…A German study found 26 skin-related adverseevents in 212 patients (12%) who received vedolizumab; more than half of these cases consisted of acne. 2 Psoriasiform dermatitis was observed in three case reports;[3][4][5] lesions resolved in two cases after vedolizumab cessation 3,5. Our case was unique with its pediatric onset and resolution of eruption with topical treatment.The mechanism underlying the development of psoriasiform dermatitis remains unclear.…”